We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.01% | 91.89 | 91.87 | 91.89 | 92.17 | 91.57 | 91.83 | 237,544 | 12:47:49 |
From May 2022 to May 2024
By Cecilia Butini
Sanofi SA said Thursday that the European Union gave marketing authorization to a drug it developed to treat hemolytic anemia in adult patients with cold agglutinin disease, an autommune disease targeting red blood cells.
The French pharma company said that its drug, a monoclonal antibody named Enjaymo, is currently the only approved treatment for the disease.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
November 17, 2022 13:14 ET (18:14 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
